Eric Jonasch, MD, on phase 1/2 trial of 177Lu-girentuximab combination in ccRCC
December 18th 2024“We really want to understand whether by using this beta emitter, together with the combination of cabazantinib and the nivolumab, we're getting better outcomes than we would expect with the doublet alone,” says Eric Jonasch, MD.